Celularity INC 8-K filings

Celularity Inc. has amended the exercise price of outstanding warrants, leading to the exercise of these warrants and generating approximately $2.46 million in gross proceeds for the company.

Celularity Inc.'s private placement agreement with an institutional investor has expired due to the non-receipt of the subscription amount, resulting in the cancellation of the planned sale of shares and warrants.

Celularity Inc. has issued warrants to purchase 1,263,157 shares of its Class A common stock as part of a private placement agreement.

Celularity Inc. held its Annual Meeting of Stockholders on December 19, 2024, where stockholders voted on the election of a Class III Director and the ratification of the company's independent auditor.

Celularity Inc. has issued warrants to Madison Global Partners, LLC, allowing them to purchase company stock at a set price, as part of a larger private placement agreement.

Celularity Inc. received a notice from Nasdaq for failing to file its Q3 2024 report on time, potentially leading to delisting if compliance is not regained.

Celularity Inc. has set the date for its 2024 Annual Meeting of Stockholders for December 19, 2024, and established deadlines for stockholder proposals.

Celularity increased its full-year 2024 net sales guidance to $54-$60 million, driven by strong sales of its advanced biomaterial products and a record-breaking October.

Celularity Inc. reports strong revenue from biomaterial products and provides an update on its product pipeline and regulatory filings.

Celularity Inc. is facing potential delisting from the Nasdaq Capital Market due to its failure to file required quarterly reports, despite a previous extension.

Celularity Inc. has acquired the Rebound allograft matrix product from Sequence LifeScience, Inc. for $5.5 million, aiming to boost its biomaterial sales.

Celularity Inc. reports the resignation of its Executive Vice President and Chief Medical Officer, Adrian Kilcoyne, effective August 6, 2024.

Celularity Inc. has appointed Richard J. Berman to its Board of Directors and reduced the board size from seven to six members following recent departures.

Celularity Inc. has received a formal notice from Nasdaq for failing to file its Q2 2024 financial report on time, adding to its existing delinquency with the Q1 2024 report.

Celularity Inc. has dismissed Deloitte & Touche LLP as its independent auditor and engaged EisnerAmper LLP, while also seeing the resignation of a board member, Marc Mazur.

Celularity Inc. received a notice from Nasdaq for failing to file its Q1 2024 report and remaining delinquent on its 2023 annual report, potentially leading to delisting.

Celularity Inc. reports preliminary net revenue of approximately $12.1 million for Q4 2023 and $14.8 million for Q1 2024, alongside hosting an Investor and Analyst Research & Development Day.

Celularity Inc. received a notice from Nasdaq for failing to file its 2023 annual report on time, putting its listing status at risk.

Celularity Inc. has entered into a standby equity purchase agreement with YA II PN, Ltd for up to $10 million, along with related forbearance agreements with Resorts World Inc Pte Ltd and C.V. Starr & Co. Inc.

Celularity Inc. has approved a 1-for-10 reverse stock split of its Class A common stock, effective February 28, 2024, to increase the per-share trading price.

Celularity Inc. has reduced executive base salaries by 15% for 2024, with a larger 85% reduction for the CEO, and granted stock options, as part of an agreement with Dragasac Limited.

Celularity Inc. has released an updated business description, highlighting its focus on developing cellular and regenerative medicine therapies derived from the placenta.

Celularity Inc. has entered into a series of agreements to secure $21 million in funding through a private placement and an amended loan agreement, aimed at addressing debt and operational needs.